AU2006209547C1 - Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor - Google Patents

Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor Download PDF

Info

Publication number
AU2006209547C1
AU2006209547C1 AU2006209547A AU2006209547A AU2006209547C1 AU 2006209547 C1 AU2006209547 C1 AU 2006209547C1 AU 2006209547 A AU2006209547 A AU 2006209547A AU 2006209547 A AU2006209547 A AU 2006209547A AU 2006209547 C1 AU2006209547 C1 AU 2006209547C1
Authority
AU
Australia
Prior art keywords
cancer
ftd
day
dose
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2006209547A
Other languages
English (en)
Other versions
AU2006209547A1 (en
AU2006209547B2 (en
Inventor
Tomohiro Emura
Akira Mita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006209547(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of AU2006209547A1 publication Critical patent/AU2006209547A1/en
Application granted granted Critical
Publication of AU2006209547B2 publication Critical patent/AU2006209547B2/en
Publication of AU2006209547C1 publication Critical patent/AU2006209547C1/en
Assigned to LES LABORATORIES SERVIER reassignment LES LABORATORIES SERVIER Request for Assignment Assignors: TAIHO PHARMACEUTICAL CO., LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006209547A 2005-01-26 2006-01-25 Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor Expired AU2006209547C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/042,059 2005-01-26
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
JP2005-165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (3)

Publication Number Publication Date
AU2006209547A1 AU2006209547A1 (en) 2006-08-03
AU2006209547B2 AU2006209547B2 (en) 2011-05-26
AU2006209547C1 true AU2006209547C1 (en) 2022-04-07

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006209547A Expired AU2006209547C1 (en) 2005-01-26 2006-01-25 Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Country Status (21)

Country Link
EP (1) EP1849470B2 (cg-RX-API-DMAC10.html)
JP (1) JP5576591B2 (cg-RX-API-DMAC10.html)
KR (1) KR101468216B1 (cg-RX-API-DMAC10.html)
AU (1) AU2006209547C1 (cg-RX-API-DMAC10.html)
BE (1) BE2017C028I2 (cg-RX-API-DMAC10.html)
CA (1) CA2594713A1 (cg-RX-API-DMAC10.html)
CY (2) CY2017029I1 (cg-RX-API-DMAC10.html)
DK (1) DK1849470T4 (cg-RX-API-DMAC10.html)
ES (1) ES2630002T5 (cg-RX-API-DMAC10.html)
FI (1) FI1849470T4 (cg-RX-API-DMAC10.html)
FR (1) FR17C1028I2 (cg-RX-API-DMAC10.html)
HU (2) HUE033306T2 (cg-RX-API-DMAC10.html)
LT (2) LT1849470T (cg-RX-API-DMAC10.html)
LU (1) LUC00036I2 (cg-RX-API-DMAC10.html)
NL (1) NL300889I2 (cg-RX-API-DMAC10.html)
PL (1) PL1849470T5 (cg-RX-API-DMAC10.html)
PT (1) PT1849470T (cg-RX-API-DMAC10.html)
RU (1) RU2394581C2 (cg-RX-API-DMAC10.html)
SI (1) SI1849470T2 (cg-RX-API-DMAC10.html)
TW (1) TWI362265B (cg-RX-API-DMAC10.html)
WO (1) WO2006080327A1 (cg-RX-API-DMAC10.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
RU2394581C2 (ru) 2005-01-26 2010-07-20 Тайхо Фармасьютикал Ко., Лтд. ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8536188B2 (en) 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
US20110065663A1 (en) * 2008-05-15 2011-03-17 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer combination therapy
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
MX2012000317A (es) 2009-07-22 2012-02-08 Gruenenthal Gmbh Forma de dosificacion de liberacion controlada extruida por fusion en caliente.
JP5933553B2 (ja) 2010-09-02 2016-06-15 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
SI2736495T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
SMT201800108T1 (it) * 2011-08-16 2018-05-02 Taiho Pharmaceutical Co Ltd Agente antitumorale e metodo di previsione dell'effetto terapeutico per pazienti con cancro colorettale con kras mutato
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
JP6030119B2 (ja) 2012-03-14 2016-11-24 日清ファルマ株式会社 含硫アミノ酸含有組成物
TR201815502T4 (tr) 2012-04-18 2018-11-21 Gruenenthal Gmbh Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
AU2014245146B2 (en) * 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including irinotecan hydrochloride hydrate
AU2014245147B2 (en) * 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including low-dose irinotecan hydrochloride hydrate
NZ714014A (en) * 2013-05-17 2017-06-30 Taiho Pharmaceutical Co Ltd Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
DK3042669T3 (da) 2013-09-06 2023-06-12 Taiho Pharmaceutical Co Ltd Antitumormiddel og forstærker af antitumorvirkning
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6871868B2 (ja) * 2016-01-08 2021-05-19 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
KR102412690B1 (ko) 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2238331C (en) * 1996-09-24 2003-02-25 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
RU2394581C2 (ru) 2005-01-26 2010-07-20 Тайхо Фармасьютикал Ко., Лтд. ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
US6294535B1 (en) * 1995-03-29 2001-09-25 Taiho Pharmaceutical Co., Ltd. Uracil derivatives and antitumor effect potentiator and antitumor agent containing the same

Also Published As

Publication number Publication date
LTC1849470I2 (lt) 2019-10-25
PT1849470T (pt) 2017-09-22
DK1849470T3 (en) 2017-08-14
LUC00036I2 (cg-RX-API-DMAC10.html) 2017-12-01
EP1849470A1 (en) 2007-10-31
LT1849470T (lt) 2017-07-25
ES2630002T3 (es) 2017-08-17
TW200637562A (en) 2006-11-01
PL1849470T5 (pl) 2024-06-10
WO2006080327A1 (ja) 2006-08-03
KR20070104559A (ko) 2007-10-26
EP1849470B2 (en) 2024-03-20
TWI362265B (en) 2012-04-21
LUC00036I1 (cg-RX-API-DMAC10.html) 2017-10-02
BE2017C028I2 (cg-RX-API-DMAC10.html) 2025-09-10
JPWO2006080327A1 (ja) 2008-06-19
FR17C1028I2 (fr) 2018-11-02
SI1849470T1 (sl) 2017-10-30
NL300889I2 (nl) 2018-01-16
ES2630002T5 (es) 2024-09-19
FR17C1028I1 (cg-RX-API-DMAC10.html) 2017-09-29
CY2017029I2 (el) 2018-02-14
CY2017029I1 (el) 2018-02-14
KR101468216B1 (ko) 2014-12-03
DK1849470T4 (en) 2024-04-02
PL1849470T3 (pl) 2017-11-30
RU2007132181A (ru) 2009-03-10
EP1849470A4 (en) 2010-12-08
AU2006209547A1 (en) 2006-08-03
AU2006209547B2 (en) 2011-05-26
HUE033306T2 (hu) 2017-11-28
RU2394581C2 (ru) 2010-07-20
HUS1700032I1 (hu) 2017-09-28
SI1849470T2 (sl) 2024-05-31
CY1119393T1 (el) 2018-02-14
EP1849470B1 (en) 2017-06-21
NL300889I1 (nl) 2017-08-14
JP5576591B2 (ja) 2014-08-20
FI1849470T4 (fi) 2024-03-22
LTPA2017024I1 (lt) 2017-08-10
CA2594713A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
AU2006209547C1 (en) Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
US20090281105A1 (en) Radiotherapy enhancer
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
TWI401085B (zh) Contains cytosine derivatives for continuous intravenous administration with anti-tumor agents
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
JPWO2012105486A1 (ja) １日１回隔日投与を特徴とするテガフール含有組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 DEC 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 03 DEC 2021

PC Assignment registered

Owner name: LES LABORATORIES SERVIER

Free format text: FORMER OWNER(S): TAIHO PHARMACEUTICAL CO., LTD.

TH Corrigenda

Free format text: IN VOL 59 , NO 51 , PAGE(S) 7206 UNDER THE HEADING ASSIGNMENTS REGISTERED CORRECT THE NAME OF THE ASSIGNEE TO READ: LES LABORATOIRES SERVIER.